HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OCUL
Ocular Therapeutix, Inc.
OCUL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OCUL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
OCUL's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OCUL PE Valuation
OCUL has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OCUL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect OCUL's losses to grow, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over OCUL on earnings, with more consistent year-over-year improvement.
OCUL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | -$0.04 |
| Q2 2026 | -$1.40 | -$0.16 |
| Q1 2026 | -$1.44 | -$0.33 |
| Q4 2025 | -$1.42 | -$0.20 |
| Q3 2025 | -$1.40 | -$0.31 |
| Q2 2025 | -$1.24 | -$0.12 |
| Q1 2025 | -$1.11 | +$0.01 |
| Q4 2024 | -$1.22 | -$0.20 |
OCUL is still losing money, but less than at its worst: $1.44 per share over the past year, against $2.56 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OCUL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OCUL on profitability, with a higher operating margin.
OCUL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.9M | -11% |
| Q2 2026 | $13.5M | +0.1% |
| Q1 2026 | $10.8M | +0.8% |
| Q4 2025 | $13.3M | -22% |
| Q3 2025 | $14.5M | -5.7% |
| Q2 2025 | $13.5M | -18% |
| Q1 2025 | $10.7M | -28% |
| Q4 2024 | $17.1M | +15% |
OCUL's revenue has slid since its 2024 peak: $13M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -760% | -288 points |
| Q2 2026 | -609% | -107 points |
| Q1 2026 | -865% | -268 points |
| Q4 2025 | -526% | -230 points |
| Q3 2025 | -472% | -174 points |
| Q2 2025 | -503% | -237 points |
| Q1 2025 | -597% | -384 points |
| Q4 2024 | -296% | -161 points |
OCUL's operating margin was −760% last quarter, down 288 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OCUL on cash generation, producing positive trailing cash flow while its opponent burns cash.
OCUL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$68.7M | -$11.9M |
| Q2 2026 | -$70.6M | -$14.2M |
| Q1 2026 | -$70.7M | -$24.1M |
| Q4 2025 | -$57.1M | -$17.5M |
| Q3 2025 | -$56.7M | -$20.1M |
| Q2 2025 | -$56.5M | -$30.9M |
| Q1 2025 | -$46.6M | -$12.5M |
| Q4 2024 | -$39.6M | -$16.7M |
OCUL has burned cash in almost every quarter: −$267M over the past year, against −$199M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OCUL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OCUL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +563K shares |
| 1 year | +23% | +41.6M shares |
| 3 years | +189% | +147M shares |
| 5 years | +175% | +143M shares |
| Available history | +398% | +180M shares |
OCUL has 226M diluted shares, up 23% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OCUL Net Leverage
OCUL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OCUL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 10.7 | Oversold |
OCUL's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OCUL PE vs Healthcare Sector
OCUL has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OCUL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% below |
| 20 week MA | $8.73 | 28% below |
| 50 week MA | $9.37 | 33% below |
| 100 week MA | $9.49 | 34% below |
| 200 week MA | $7.82 | 20% below |
OCUL is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over OCUL on returns for 2026, with the stronger performance.
OCUL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.19 | $22.1 | +427% |
| 2021 | $22.1 | $7.22 | -67% |
| 2022 | $7.22 | $2.67 | -63% |
| 2023 | $2.67 | $4.46 | +67% |
| 2024 | $4.46 | $8.44 | +89% |
| 2025 | $8.44 | $12.6 | +49% |
| 2026 YTD | $12.6 | $6.28 | -50% |
OCUL's yearly returns have swung widely, from +427% in 2020 to −67% in 2021. It's down 50% so far in 2026.